#1 Clinical Trials Search in Europe

Dazostinag

Dazostinag, a novel drug under investigation, is currently being studied in clinical trials for the treatment of advanced or metastatic solid tumors. This article explores the ongoing research on Dazostinag, both as a single agent and in combination with other therapies, to evaluate its safety, efficacy, and potential benefits for cancer patients.

Table of Contents

What is Dazostinag?

Dazostinag, also known as TAK-676, is a new drug being tested for the treatment of advanced or metastatic solid tumors[1]. Solid tumors are abnormal masses of tissue that don’t contain cysts or liquid areas. They can occur in many parts of the body, such as the lungs, breast, or colon. When a tumor is described as “advanced” or “metastatic,” it means the cancer has spread from its original location to other parts of the body.

How is Dazostinag Being Studied?

Dazostinag is currently being investigated in a clinical trial to determine its safety, how well patients tolerate it, and how it works in the body[1]. The study is being conducted in two main phases:

  1. Dose Escalation Phase: This phase aims to find the right dose of Dazostinag that can be given safely. Researchers start with a low dose and gradually increase it to determine the highest dose that doesn’t cause severe side effects.
  2. Dose Expansion Phase: Once a safe dose is determined, more patients are given the drug to further study its effects and safety.

The study is also looking at how Dazostinag works when given alone and when combined with another drug called pembrolizumab, which is an immunotherapy drug that helps the immune system fight cancer cells[1].

What Conditions Does Dazostinag Treat?

Dazostinag is being studied to treat various types of advanced or metastatic solid tumors. Specifically, the research is focusing on[1]:

  • Squamous Cell Carcinoma of Head and Neck (SCCHN): This is a type of cancer that starts in the flat cells lining the inside of the mouth, nose, and throat.
  • Colorectal Cancer (CRC): This is cancer that starts in the colon or rectum. The study is looking at two types of CRC:
    • MSI-H/dMMR CRC: This type has a high level of genetic instability.
    • MSS/pMMR CRC: This type has a normal level of genetic stability.

How is Dazostinag Administered?

Dazostinag is given as an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein[1]. The drug is typically administered once a week (on days 1, 8, and 15) in 21-day treatment cycles. The exact dose may vary depending on the phase of the study and the individual patient’s response to the treatment.

Potential Side Effects and Safety

As with any new drug, one of the main goals of the study is to assess the safety of Dazostinag and identify any potential side effects[1]. The researchers are carefully monitoring for what they call “treatment-emergent adverse events” (TEAEs), which are any unfavorable and unintended signs, symptoms, or diseases that occur during the treatment period.

The severity of side effects is graded on a scale from 1 to 5, with 1 being mild and 5 being death related to the side effect. The study is also looking for “dose-limiting toxicities” (DLTs), which are side effects severe enough to prevent increasing the dose of the drug.

Combination Therapy

In addition to studying Dazostinag on its own, researchers are also investigating how it works in combination with other treatments[1]:

  • Pembrolizumab: This is an immunotherapy drug that helps the body’s immune system detect and fight cancer cells.
  • Chemotherapy: In some parts of the study, Dazostinag is being combined with standard chemotherapy drugs like carboplatin, cisplatin, and 5-fluorouracil.

What to Expect During Treatment

If you’re participating in this clinical trial, you can expect[1]:

  • Regular visits to the clinic for treatment and check-ups
  • Blood tests to measure how the drug is processed by your body
  • Scans to assess how your tumor is responding to the treatment
  • Close monitoring for any side effects
  • Follow-up visits after treatment ends

The entire study is expected to last about 62.9 months, with individual participation varying depending on how a patient responds to the treatment.

Aspect Details
Study Type Phase 1/2 clinical trial
Primary Objectives Assess safety, tolerability, and determine optimal dosage of Dazostinag
Treatment Groups Dazostinag alone, Dazostinag + Pembrolizumab, Dazostinag + Pembrolizumab + Chemotherapy
Cancer Types Advanced solid tumors, SCCHN, MSI-H/dMMR CRC, MSS/pMMR CRC
Key Outcomes Measured Adverse events, pharmacokinetics, overall response rate, disease control rate, progression-free survival, overall survival
Study Duration Approximately 62.9 months

FAQ

  • What is Dazostinag? Dazostinag is an experimental drug being tested for the treatment of advanced or metastatic solid tumors. It is being studied both as a single agent and in combination with other therapies, such as pembrolizumab.
  • What types of cancer is Dazostinag being tested for? Dazostinag is being tested for various types of advanced solid tumors, including squamous cell carcinoma of the head and neck (SCCHN) and colorectal cancer (CRC).
  • How is Dazostinag administered? Dazostinag is administered through intravenous (IV) infusion, typically once weekly on Days 1, 8, and 15 in 21-day treatment cycles.
  • What are the main goals of the clinical trials involving Dazostinag? The main goals are to assess the safety, tolerability, and effectiveness of Dazostinag. Researchers are also studying how the drug behaves in the body (pharmacokinetics) and its effects on the body (pharmacodynamics).
  • Are there any combinations being tested with Dazostinag? Yes, Dazostinag is being tested in combination with pembrolizumab, a known immunotherapy drug. In some cases, it's also being studied with chemotherapy drugs like carboplatin, cisplatin, and 5-fluorouracil.

Ongoing Clinical Trials on Dazostinag

  • Study of Dazostinag and Pembrolizumab for Adults with Advanced or Metastatic Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Poland

Glossary

  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Solid Tumors: Abnormal masses of tissue that don't contain cysts or liquid areas. Solid tumors may be benign or malignant.
  • Pembrolizumab: An immunotherapy drug that helps the immune system detect and fight cancer cells.
  • Squamous Cell Carcinoma of Head and Neck (SCCHN): A type of cancer that begins in the squamous cells lining the mouth, nose, and throat.
  • Colorectal Cancer (CRC): Cancer that starts in the colon or rectum.
  • Microsatellite Instability-High (MSI-H): A condition where cells have a high number of genetic mutations in microsatellites, which are short, repeated sequences of DNA.
  • Mismatch Repair Deficient (dMMR): A condition where cells have mutations in genes responsible for fixing mistakes in DNA replication.
  • Intravenous (IV) Infusion: A method of delivering medications directly into the bloodstream through a vein.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics: The study of a drug's effects on the body, including its mechanism of action and relationship between drug concentration and effect.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a decrease in dosage.
  • Response Evaluation Criteria in Solid Tumors (RECIST): A standard way to measure how well a cancer patient responds to treatment based on whether tumors shrink, stay the same, or get bigger.

References